These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20415601)

  • 21. Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
    Imprialos K; Koutsampasopoulos K; Manolis A; Doumas M
    Curr Vasc Pharmacol; 2021; 19(3):301-312. PubMed ID: 32286949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
    Fanbin L; Mei Y; Yan Z; Yirong Y; Shaoling Z; Yong C; Peng X
    Exp Clin Transplant; 2014 Jun; 12(3):184-9. PubMed ID: 24907716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Avanafil - a further step to tailoring patient needs and expectations.
    Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
    Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
    Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism.
    Wang C; Zhang H; Wang F; Guo J; Yuan J; Hou G; Gao M; Li Z; Zhang Y;
    Aging Male; 2024 Dec; 27(1):2288347. PubMed ID: 38146937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model.
    Yilmaz-Oral D; Kaya-Sezginer E; Oztekin CV; Bayatli N; Lokman U; Gur S
    Neurourol Urodyn; 2020 Apr; 39(4):1087-1097. PubMed ID: 32150290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
    Limin M; Johnsen N; Hellstrom WJ
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction.
    Khan S; Amjad A; Rowland D
    J Sex Med; 2019 Feb; 16(2):300-306. PubMed ID: 30770073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Color Doppler Duplex Ultrasound Parameters in Men Without Organic Erectile Dysfunction.
    Pathak RA; Broderick GA
    Urology; 2020 Jan; 135():66-70. PubMed ID: 31541647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Importance of patient's choice in the treatment of erectile dysfunction].
    Corman A; Chevret-Méasson M; Gehchan N
    Presse Med; 2012 Jun; 41(6 Pt 1):593-7. PubMed ID: 22377459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs in preclinical to phase II clinical development for the treatment of erectile dysfunction.
    Smith-Harrison L; Starke NR; Smith RP; Kovac JR
    Expert Opin Investig Drugs; 2017 Jun; 26(6):669-675. PubMed ID: 28460540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BPH/LUTS and ED: common pharmacological pathways for a common treatment.
    Fusco F; D'Anzeo G; Sessa A; Pace G; Rossi A; Capece M; d'Emmanuele di Villa Bianca R
    J Sex Med; 2013 Oct; 10(10):2382-93. PubMed ID: 23875757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatment options for erectile dysfunction in patients with diabetes mellitus.
    Basu A; Ryder RE
    Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of sexual function outcome after radical prostatectomy using phosphodiesterase type 5 inhibitors.
    Kaiho Y; Yamashita S; Arai Y
    Int J Urol; 2013 Mar; 20(3):285-9. PubMed ID: 23311962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advances in the studies of refractory erectile dysfunction].
    Wang BY; Jiang R
    Zhonghua Nan Ke Xue; 2013 Jan; 19(1):82-5. PubMed ID: 23469669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials.
    Du W; Li J; Fan N; Shang P; Wang Z; Ding H
    Aging Male; 2014 Jun; 17(2):107-11. PubMed ID: 24219508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding Erectile Dysfunction in Hypertensive Patients: The Need for Good Patient Management.
    Hernández-Cerda J; Bertomeu-González V; Zuazola P; Cordero A
    Vasc Health Risk Manag; 2020; 16():231-239. PubMed ID: 32606719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central nervous system agents and erectile dysfunction.
    Kumar R; Nehra A
    Urol Clin North Am; 2011 May; 38(2):165-73. PubMed ID: 21621083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.